Company attributes
Other attributes
Massive Bio is a New York-based advanced oncology advisory service that provides patients with physicians, diagnostic testing, clinical trials, and treatment plans from various healthcare networks worldwide. Massive Bio was founded by Selin Kurnaz, Arturo Loaiza Bonilla, and Cagatay M. Culcuoglu in May of 2015 to develop artificial intelligence programs that match patients with suitable treatments.
Massive Bio developed an AI called SYNERGY AI that matches patients and their oncologists to clinical trials while allowing pharmaceutical companies access to patients and their treatment information for drug development. The AI can match patients to trails located anywhere in the world if the patient is eligible. SYNERGY AI also acts as a registry for patients and clinical trials, allowing patients to be matched if they fit newly posted trial criteria.
When patients are not matched to clinical trials, Massive Bio refers patients to its Virtual Tumor Board. The board is comprised of physicians, diagnosticians, and clinical sub-specialists from 25 cancer research and treatment facilities across the United States. When a new patient is referred to the Virtual Tumor Board, several professionals collaborate on the patient case to formulate new care plans, treatment plans, and testing. Massive Bio states that treating patients this way reduces time and money spent on travel without jeopardizing care standards.
